RS67627B1 - Rifabutinske kompozicije i način pripreme - Google Patents
Rifabutinske kompozicije i način pripremeInfo
- Publication number
- RS67627B1 RS67627B1 RS20251344A RSP20251344A RS67627B1 RS 67627 B1 RS67627 B1 RS 67627B1 RS 20251344 A RS20251344 A RS 20251344A RS P20251344 A RSP20251344 A RS P20251344A RS 67627 B1 RS67627 B1 RS 67627B1
- Authority
- RS
- Serbia
- Prior art keywords
- rifabutin
- solution
- acid
- formulation
- solvent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899257P | 2019-09-12 | 2019-09-12 | |
| US201962902019P | 2019-09-18 | 2019-09-18 | |
| US201962941160P | 2019-11-27 | 2019-11-27 | |
| EP20768379.8A EP4027976B1 (en) | 2019-09-12 | 2020-08-03 | Rifabutin compositions and method of making |
| PCT/IB2020/000648 WO2021048612A1 (en) | 2019-09-12 | 2020-08-03 | Rifabutin treatment methods, uses, and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS67627B1 true RS67627B1 (sr) | 2026-02-27 |
Family
ID=72428294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20251344A RS67627B1 (sr) | 2019-09-12 | 2020-08-03 | Rifabutinske kompozicije i način pripreme |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US12370184B2 (https=) |
| EP (1) | EP4027976B1 (https=) |
| JP (2) | JP7777518B2 (https=) |
| KR (1) | KR20220103697A (https=) |
| CN (4) | CN113015519B (https=) |
| AU (2) | AU2020346414B2 (https=) |
| BR (1) | BR112022004659A2 (https=) |
| CA (1) | CA3154318A1 (https=) |
| DK (1) | DK4027976T3 (https=) |
| ES (1) | ES3056897T3 (https=) |
| FI (1) | FI4027976T3 (https=) |
| HR (1) | HRP20251645T1 (https=) |
| LT (1) | LT4027976T (https=) |
| MX (1) | MX2022003075A (https=) |
| MY (1) | MY210244A (https=) |
| PH (1) | PH12022550606A1 (https=) |
| PL (1) | PL4027976T3 (https=) |
| PT (1) | PT4027976T (https=) |
| RS (1) | RS67627B1 (https=) |
| SI (1) | SI4027976T1 (https=) |
| SM (1) | SMT202500491T1 (https=) |
| WO (1) | WO2021048612A1 (https=) |
| ZA (1) | ZA202203357B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230364065A1 (en) * | 2022-05-16 | 2023-11-16 | BioVersys AG | Antibiotic combination therapies |
| WO2026022215A1 (en) * | 2024-07-23 | 2026-01-29 | BioVersys AG | Lyophilized formulations of rifabutin |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6645508B1 (en) | 1999-06-18 | 2003-11-11 | Jivn-Ren Chen | Stable L-ascorbic acid composition |
| CN1775214A (zh) * | 2005-11-18 | 2006-05-24 | 武汉大学 | 利福喷丁、利福平、利福布丁或利福定注射剂及其制备方法 |
| NZ571989A (en) * | 2006-03-23 | 2012-07-27 | Agriculture Victoria Serv Pty | Antimicrobial protein |
| CN101362067A (zh) | 2007-08-06 | 2009-02-11 | 天津科技大学 | 一种微胶囊制备方法 |
| MY158809A (en) * | 2010-09-22 | 2016-11-15 | Craun Res Sdn Bhd | Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same |
| EA016410B1 (ru) * | 2010-11-13 | 2012-04-30 | Ооо "Нпк Наносистема" | Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты) |
| CA2826192A1 (en) | 2011-01-31 | 2012-08-09 | The Government Of The United States, As Represented By The Secretary Of The Army | Methods and compositions for treating bacterial infections with iron chelators |
| CN102178604B (zh) * | 2011-03-22 | 2014-03-05 | 中国人民解放军第三0九医院 | 凝胶微球制备装置、方法及可注射抗结核药物凝胶微球 |
| RU2015133801A (ru) * | 2014-01-09 | 2017-02-16 | Камус Фарма Пвт. Лтд. | Лиофилизированные составы для парентерального применения |
| WO2016014437A1 (en) * | 2014-07-21 | 2016-01-28 | Hiroaki Serizawa | Ophthalmic compositions of rifamycins and uses thereof |
| US9763996B2 (en) | 2015-01-16 | 2017-09-19 | Northern Antibiotics, Ltd. | Polymyxin derivative and uses thereof |
| WO2016178240A1 (en) * | 2015-05-04 | 2016-11-10 | Gufic Biosciences Limited | A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof |
| KR20190116320A (ko) | 2017-02-07 | 2019-10-14 | 에스티씨. 유엔엠 | 오래 지속되는 자가 포식 유도를 위한 동위 원소 강화 암브록솔 |
| US11701346B2 (en) | 2018-11-28 | 2023-07-18 | University Of Southern California | Rifabutin for the treatment of acinetobacter baumannii |
-
2020
- 2020-08-03 LT LTEPPCT/IB2020/000648T patent/LT4027976T/lt unknown
- 2020-08-03 SM SM20250491T patent/SMT202500491T1/it unknown
- 2020-08-03 ES ES20768379T patent/ES3056897T3/es active Active
- 2020-08-03 CN CN202080005144.XA patent/CN113015519B/zh active Active
- 2020-08-03 CN CN202510450436.9A patent/CN120267667A/zh active Pending
- 2020-08-03 KR KR1020227012083A patent/KR20220103697A/ko not_active Ceased
- 2020-08-03 MX MX2022003075A patent/MX2022003075A/es unknown
- 2020-08-03 EP EP20768379.8A patent/EP4027976B1/en active Active
- 2020-08-03 BR BR112022004659A patent/BR112022004659A2/pt unknown
- 2020-08-03 CN CN202510450439.2A patent/CN120267668A/zh active Pending
- 2020-08-03 PL PL20768379.8T patent/PL4027976T3/pl unknown
- 2020-08-03 CA CA3154318A patent/CA3154318A1/en active Pending
- 2020-08-03 PH PH1/2022/550606A patent/PH12022550606A1/en unknown
- 2020-08-03 MY MYPI2022001371A patent/MY210244A/en unknown
- 2020-08-03 DK DK20768379.8T patent/DK4027976T3/da active
- 2020-08-03 RS RS20251344A patent/RS67627B1/sr unknown
- 2020-08-03 FI FIEP20768379.8T patent/FI4027976T3/fi active
- 2020-08-03 CN CN202510450433.5A patent/CN120267666A/zh active Pending
- 2020-08-03 JP JP2022516162A patent/JP7777518B2/ja active Active
- 2020-08-03 PT PT207683798T patent/PT4027976T/pt unknown
- 2020-08-03 SI SI202030697T patent/SI4027976T1/sl unknown
- 2020-08-03 HR HRP20251645TT patent/HRP20251645T1/hr unknown
- 2020-08-03 AU AU2020346414A patent/AU2020346414B2/en active Active
- 2020-08-03 WO PCT/IB2020/000648 patent/WO2021048612A1/en not_active Ceased
-
2022
- 2022-03-22 ZA ZA2022/03357A patent/ZA202203357B/en unknown
-
2023
- 2023-09-12 US US18/465,226 patent/US12370184B2/en active Active
-
2025
- 2025-11-17 JP JP2025196675A patent/JP2026027477A/ja active Pending
- 2025-12-17 AU AU2025283482A patent/AU2025283482A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7777518B2 (ja) | 2025-11-28 |
| HRP20251645T1 (hr) | 2026-02-13 |
| MX2022003075A (es) | 2022-07-11 |
| AU2020346414B2 (en) | 2025-10-02 |
| AU2020346414A1 (en) | 2022-04-14 |
| SMT202500491T1 (it) | 2026-03-09 |
| CA3154318A1 (en) | 2021-03-18 |
| FI4027976T3 (fi) | 2025-12-12 |
| MY210244A (en) | 2025-09-04 |
| ES3056897T3 (en) | 2026-02-25 |
| AU2025283482A1 (en) | 2026-01-15 |
| EP4027976A1 (en) | 2022-07-20 |
| KR20220103697A (ko) | 2022-07-22 |
| LT4027976T (lt) | 2026-01-12 |
| SI4027976T1 (sl) | 2026-02-27 |
| DK4027976T3 (da) | 2025-12-22 |
| WO2021048612A1 (en) | 2021-03-18 |
| CN113015519B (zh) | 2025-03-28 |
| PT4027976T (pt) | 2025-12-23 |
| PL4027976T3 (pl) | 2026-02-16 |
| CN113015519A (zh) | 2021-06-22 |
| CN120267668A (zh) | 2025-07-08 |
| US12370184B2 (en) | 2025-07-29 |
| ZA202203357B (en) | 2023-12-20 |
| JP2022548858A (ja) | 2022-11-22 |
| BR112022004659A2 (pt) | 2022-06-21 |
| CN120267667A (zh) | 2025-07-08 |
| JP2026027477A (ja) | 2026-02-18 |
| CN120267666A (zh) | 2025-07-08 |
| EP4027976B1 (en) | 2025-10-01 |
| US20240000759A1 (en) | 2024-01-04 |
| PH12022550606A1 (en) | 2023-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016385362B2 (en) | Long acting injectable formulations | |
| US20250360115A1 (en) | Rifabutin treatment methods, uses, and compositions | |
| AU2025283482A1 (en) | Rifabutin treatment methods, uses, and compositions | |
| CN106963759B (zh) | 用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3-奎宁环酮衍生物的水溶液 | |
| SA518391187B1 (ar) | طرق لإنتاج صيغ علاجية ثابتة في مذيبات قطبية لا بروتونية | |
| JP6832281B2 (ja) | バンコマイシンの水溶液製剤 | |
| BR112015023523B1 (pt) | Composições farmacêuticas e recipiente de forma de dosagem única | |
| KR102656841B1 (ko) | 레파뮬린의 주사가능한 약제학적 제형 | |
| RS59852B1 (sr) | Fiziološki balansirane injektabilne formulacije fosnetupitanta | |
| EP2922530B1 (en) | Caspofungin acetate formulations | |
| AU2004314154B2 (en) | Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same | |
| WO2023281441A1 (en) | Stabilization of phenobarbital sodium for injection | |
| CN104800172B (zh) | 注射用卡络磺钠粉针剂和制法 | |
| HK40073481A (en) | Rifabutin compositions and method of making | |
| HK40073481B (en) | Rifabutin compositions and method of making | |
| JP2026505092A (ja) | 注射用組成物、それを含む医薬製剤及びその製造方法 | |
| RU2367472C1 (ru) | Парентеральное лекарственное средство и способ его получения | |
| JPH07196507A (ja) | 静脈注射用ラパマイシン製剤 | |
| WO2019130228A1 (en) | Stable liquid compositions of melphalan | |
| KR20120000510A (ko) | 난용성 트리사이클릭 유도체 화합물의 용해도가 향상된 약학적 조성물 | |
| WO2023209731A1 (en) | Injectable liquid or lyophilized powder dosage forms of selexipag and their method of preparation | |
| HK1215668B (en) | Caspofungin acetate formulations |